Diamedizen MR tablets are an important medication in the management and treatment of type 2 diabetes, a chronic disease that requires careful control of blood sugar levels to prevent long-term complications. This medication contains the active ingredient gliclazide in a 60 mg dose in modified-release (MR) tablets. The modified-release form releases the active ingredient gliclazide slowly and steadily over 24 hours, providing continuous stimulation of insulin secretion and helping maintain normal blood sugar levels throughout the day and night with a single daily dose. Diamedizen MR is a suitable treatment option for patients who require effective and sustained blood sugar control using a sulfonylurea.
The active ingredient in Diamedizen MR
The therapeutic efficacy of Diamedizen MR tablets is primarily based on the following active ingredient:
Gliclazide: 60 mg per tablet. Gliclazide is a second-generation sulfonylurea drug known for its effectiveness in stimulating insulin secretion. The modified-release (MR) form differs from traditional rapid-release tablets in the way the drug is released into the body.
Available Strengths of Diamedizen MR
Diamedizen MR is available in various gliclazide strengths to meet diverse therapeutic needs and give physicians flexibility in adjusting the dosage to suit each patient's condition. Common strengths available on the market include:
Gliclazide 30 mg (modified-release tablets): May be used as a starting dose or for patients who require a lower dose to control their blood sugar.
Gliclazide 60 mg (modified-release tablets): This is the standard and most common strength for most patients who need good blood sugar control with a once-daily dose.
Other strengths, such as 90 mg, may be available in some markets to provide higher dosage options for patients who require it.
Mechanism of Action of Diamedizen MR
Gliclazide primarily works by stimulating the beta cells in the pancreas to secrete insulin. Its primary mechanism of action is:
Stimulating insulin secretion: Gliclazide binds to specific receptors known as sulfonylurea receptors located on the surface of beta cells in the islets of Langerhans in the pancreas. This binding leads to the closure of ATP-sensitive potassium channels, leading to depolarization of the cell membrane. As a result of depolarization, voltage-dependent calcium channels open, allowing calcium ions to enter the cell. Increasing the intracellular calcium ion concentration stimulates the movement of insulin-containing vesicles to the cell membrane and the release of stored insulin into the bloodstream.
Improved insulin response: Gliclazide may also have additional effects outside the pancreas, such as improving peripheral tissue sensitivity to insulin and reducing hepatic glucose production, but its primary effect remains on insulin secretion.
Modified-release form: The modified-release tablet formulation allows for a slow and steady release of gliclazide over 24 hours. This maintains relatively constant levels of the drug in the blood, providing continuous stimulation of insulin secretion, reducing fluctuations in blood glucose levels, and helping to control fasting and postprandial blood glucose throughout the day with a single dose.
Indications for use of Diamedizen MR
Diamedizen MR tablets are used to treat type 2 diabetes in adults in the following cases:
When adequate blood sugar control is not achieved through appropriate diet and physical activity alone: Diamedizen MR is prescribed as a drug therapy to help lower blood sugar.
As a monotherapy or in combination with other blood sugar-lowering medications: Diamedizen MR may be prescribed as initial treatment for type 2 diabetes patients or may be added to other treatments, such as metformin, when a single medication is insufficient to control blood sugar.